Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.

Ann Hematol · 2026 · PMC12909349 · PMID 41697365

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, FLT3-ITD/TKD co-mutations showed a trend toward poorer outcomes.

also in 53,322 other papers

a strong trendno p-value reported

Therefore, the observed superiority of IC over VA, particularly in the matched analysis, should be interpreted as a strong trend requiring validation.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.